AR1001 Phase 3 in Early Alzheimer's Disease (Polaris-AD)

Market
100%75%50%25%0%Apr 13 • YES 24.0%Apr 13Apr 13 • YES 12.3%Apr 13
Trade

Will the results be positive?

Paper Trading
DetailsModel PositionsModel SnapshotsOracle
Details
Primary Completion
5/1/26
Study Completion
12/1/27
Company
AriBio Co., Ltd.
Ticker
Unavailable
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
1,535
Volume
$67K
NCT
NCT05531526
Drug Description
Polaris-AD is a pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating AR1001 over 52 weeks in participants with early Alzheimer's disease. The study is active not recruiting, and the primary outcome is change in CDR-SB at Week 52.